Daniel Lynch Sells 17,500 Shares of Blueprint Medicines Corp (BPMC) Stock

Blueprint Medicines Corp (NASDAQ:BPMC) Director Daniel Lynch sold 17,500 shares of Blueprint Medicines stock in a transaction on Monday, February 12th. The stock was sold at an average price of $74.84, for a total transaction of $1,309,700.00. Following the sale, the director now owns 202,812 shares in the company, valued at approximately $15,178,450.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Shares of Blueprint Medicines Corp (BPMC) traded up $4.95 during midday trading on Wednesday, hitting $82.93. The company’s stock had a trading volume of 483,874 shares, compared to its average volume of 324,370. The company has a market capitalization of $3,159.17, a PE ratio of -22.87 and a beta of 1.16. Blueprint Medicines Corp has a 12 month low of $32.43 and a 12 month high of $92.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.28 and a current ratio of 11.28.

BPMC has been the topic of a number of recent research reports. Morgan Stanley lifted their price target on shares of Blueprint Medicines from $45.00 to $78.00 and gave the stock an “overweight” rating in a research note on Monday, October 23rd. Cowen reiterated a “buy” rating on shares of Blueprint Medicines in a research note on Tuesday, October 31st. Canaccord Genuity reiterated a “buy” rating and set a $80.00 price target (up previously from $66.00) on shares of Blueprint Medicines in a research note on Wednesday, November 1st. Zacks Investment Research downgraded shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Thursday, November 2nd. Finally, Wedbush reiterated an “outperform” rating and set a $82.00 price target (up previously from $70.00) on shares of Blueprint Medicines in a research note on Monday, November 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the company. Blueprint Medicines presently has a consensus rating of “Buy” and an average target price of $84.20.

Hedge funds and other institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN lifted its holdings in shares of Blueprint Medicines by 31.5% during the second quarter. Wells Fargo & Company MN now owns 28,827 shares of the biotechnology company’s stock valued at $1,462,000 after acquiring an additional 6,899 shares during the period. Alyeska Investment Group L.P. bought a new position in shares of Blueprint Medicines during the third quarter valued at $6,967,000. California Public Employees Retirement System bought a new position in shares of Blueprint Medicines during the second quarter valued at $314,000. Ameriprise Financial Inc. bought a new position in shares of Blueprint Medicines during the third quarter valued at $3,779,000. Finally, California State Teachers Retirement System lifted its holdings in shares of Blueprint Medicines by 43.9% during the second quarter. California State Teachers Retirement System now owns 68,861 shares of the biotechnology company’s stock valued at $3,489,000 after acquiring an additional 20,999 shares during the period. 83.79% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/14/daniel-lynch-sells-17500-shares-of-blueprint-medicines-corp-bpmc-stock.html.

About Blueprint Medicines

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply